ZYBERNO
Stock Report
Updated Sep 1, 2026

Chemomab Therapeutics Ltd. (CMMB)

Healthcare • NASDAQ

$2.78

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
25.0/100
POOR BUSINESS
Chemomab Therapeutics Ltd. (CMMB) scores 25/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.02x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,140.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Chemomab Therapeutics Ltd. (CMMB) stock report — Zyberno Score 25/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, CMMB generated -$23.88M in Owner Earnings. Capital was deployed as follows: $55.00K invested in capital expenditures. Reinvestment rate: 0.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.78
Market Cap:$19.91M

Valuation Multiples (2)

P/B Ratio:0.71x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$675.75K

Price Action & Momentum (3)

Momentum Percentile:4 / 100
% of 52-Week High:77.7%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-0.9%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-20.9%
Latest Earnings Filed:2024-08-21
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.83x
Quick Ratio:4.83x
Cash Ratio:2.97x

Leverage Analysis (3)

Debt To Equity Ttm:0.02x
Debt-to-Equity Ratio:0.02x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:26,781,000.00
Cash And Cash Equivalents:20,765,000.00
Long Term Debt:$62.00K
Net Debt:-$20.59M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$2.33M

Profitability Breakdown (2)

$0.00-$112.00M

Bottom Line Performance (3)

-$9.00M
Income Before Tax:-$28.38M
Ebitda Ttm:-111,939,000.00

Operating Expenses (5)

Operating Expenses:29,654,000.00
R And D Expense:20,730,000.00
Sga Expense:8,924,000.00
Income Tax Expense:$55.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$35.01M
Current Assets:$33.78M
Ppe Net:352,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:7,059,000.00
Current Liabilities:6,997,000.00
Long Term Debt:$62.00K
Short Term Debt:$115.00K

Equity & Capital (3)

Equity:$27.95M
Retained Earnings:-$72.57M
Common Stock:650,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,164,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:484,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$23.85M-$23.90M

Investment Activities (2)

Investing Cash Flow:$14.43M
Capital Expenditures Ttm:55,000.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:61,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$1.26

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.55

Book Value & Capital (2)

Book Value Per Share:$3.90
Cash Per Share:2.90

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:496.50
Cash Conversion Cycle:-2,494.50
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$23.88M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-0.9%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):78.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:CMMB
Company Name:Chemomab Therapeutics Ltd.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:7.16M
Shares Outstanding Basic:286.08M
Shares Outstanding Diluted:286.08M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 14:40:08 UTC
Data Timestamp:2026-08-21T12:57:17.913554
Scroll to Top